Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games
2012 provider, GSK, unveils sign celebrating its scientific contribution to the Games
Read more -
GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic aga...
Read more -
GSK takes minority stake in new spin out Autifony Therapeutics
GlaxoSmithKline plc today announced that its wholly-owned subsidiary Glaxo Group Limited (GSK) will receive a 25.4% minority equity stake, representing a £1,250,000 investm...
Read more -
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease
- IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off time” during waking hours
Read more -
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed agreements for the supply and commercialisation on an exclusive basis of the Enigma...
Read more -
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
GlaxoSmithKline (NYSE and LSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Dru...
Read more -
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel, a GSK company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam for the topical tr...
Read more -
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
Read more -
GlaxoSmithKline European regulatory update on Pandemrix™
GlaxoSmithKline (GSK) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to the product l...
Read more -
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorisation for Benlysta(belimumab...
Read more -
EU and US Regulatory Update - Votrient® (pazopanib)
GlaxoSmithKline (GSK) announced today that it has submitted a variation to the Marketing Authorisation Application to the European Medicines Agency for Votrient (pazopanib) for ...
Read more -
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport
London 2012 partner GlaxoSmithKline (GSK) today signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods fo...
Read more -
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
– GSK’s rotavirus vaccine approved for use in babies for the prevention of rotavirus gastroenteritis – Lamotrigine becomes the first treatment to be ap...
Read more -
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research
Read more -
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s
Research led by the University of East Anglia has been published in the Journal of the American Geriatrics Society i examining the long term health impacts of anticholinergic me...
Read more -
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility
GlaxoSmithKline (GSK) has agreed to pay $40.75 million, which will be divided among 37 states and the District of Columbia, as part of an agreement reached related to events dur...
Read more -
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
GlaxoSmithKline (GSK) announced today that it has entered into an agreement to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Ne...
Read more -
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga&...
Read more -
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance
GSK today announced that it has made a new offer to supply its rotavirus vaccine, Rotarix, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
Read more -
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statis...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
